These data indicate that Hv1 is expressed significantly higher in the substantia nigra of PD patients compared to control patients, and understanding the molecular pathways and mechanisms that drive PD pathogenesis could elucidate novel therapeutic targets to halt disease progression. This evidence concerns the gene HVCN1 and Parkinson disease.